CSIMarket
 


Fibrocell Science, Inc.  (FCSC)
Other Ticker:  
 

Fibrocell Science's Tangible Leverage Ratio

FCSC's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 0.54%, Tangible Leverage Ratio fell to 1.6, above the Fibrocell Science's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2019, 272 other companies have achieved lower Tangible Leverage Ratio than Fibrocell Science in the III Quarter 2019. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2019 from 1571 to 2637 .

Explain Tangible Leverage Ratio?
What is FCSC Market Share?
What are FCSC´s Total Liabilities?


FCSC Tangible Leverage Ratio (Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
(Dec 31 2018)
IV. Quarter
(Sep 30 2018)
III. Quarter
Y / Y Tangible Equity Change 5.07 % 91.08 % -4.76 % 6.11 % -
Y / Y Total Liabilities Change 127.28 % 114.83 % 53.84 % -40.4 % -56.06 %
Tangible Leverage Ratio MRQ 1.6 0.95 2.02 0.65 0.74
FCSC's Total Ranking # 2637 # 1571 # 2085 # 2634 # 1368
Seq. Tangible Equity Change -40.22 % 198.33 % -37.22 % -6.16 % 8.71 %
Seq. Total Liabilities Change 0.54 % 40.07 % 95.65 % -17.51 % -4.97 %



Tangible Leverage Ratio third quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 273
Healthcare Sector # 638
Overall Market # 2637


Tangible Leverage Ratio Statistics
High Average Low
2.02 0.8 0.06
(Mar 31 2019)   (Dec 31 2012)




Financial Statements
Fibrocell Science's Tangible Equity $ 11 Millions Visit FCSC's Balance sheet
Fibrocell Science's Total Liabilities $ 17 Millions Visit FCSC's Balance sheet
Source of FCSC's Sales Visit FCSC's Sales by Geography


Cumulative Fibrocell Science's Tangible Leverage Ratio

FCSC's Tangible Leverage Ratio for the trailling 12 Months

FCSC Tangible Leverage Ratio

(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
(Dec 31 2018)
IV. Quarter
(Sep 30 2018)
III. Quarter
Y / Y Tangible Equity TTM Growth 5.07 % 91.08 % -4.76 % 6.11 % -
Y / Y Total Liabilities TTM Growth 127.28 % 114.83 % 53.84 % -40.4 % -56.06 %
Tangible Leverage Ratio TTM 1.19 0.98 0.96 0.83 0.97
Total Ranking TTM # 2330 # 1863 # 17 # 1863 # 19
Seq. Tangible Equity TTM Growth -40.22 % 198.33 % -37.22 % -6.16 % 8.71 %
Seq. Total Liabilities TTM Growth 0.54 % 40.07 % 95.65 % -17.51 % -4.97 %


On the trailing twelve months basis Due to the net new borrowings of 0.54% during the trailing twelve months finishing in the III Quarter 2019, cumulativeTangible Leverage Ratio improved to 1.19, above the Fibrocell Science's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 272, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Fibrocell Science. While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2019, compared to the prior period, from 1863 to 2330.

Explain Tangible Leverage Ratio?
What is FCSC Market Share?
What are FCSC´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 273
Healthcare Sector # 638
Within the Market # 2330


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
2.02 0.8 0.06
(Mar 31 2019)   (Dec 31 2012)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2019 MRQ Total LiabilitiesSep 30 2019 MRQ Tangible Equity
Durect Corp  4.24 $ 66.251  Millions$ 15.607  Millions
Collegium Pharmaceutical Inc   4.11 $ 210.108  Millions$ 51.067  Millions
Novabay Pharmaceuticals Inc   4.00 $ 11.680  Millions$ 2.923  Millions
Karyopharm Therapeutics Inc   3.95 $ 236.292  Millions$ 59.870  Millions
Intelgenx Technologies Corp   3.90 $ 10.293  Millions$ 2.639  Millions
Bristol myers Squibb Company  3.89 $ 39,785.000  Millions$ 10,239.000  Millions
Theratechnologies Inc   3.73 $ 92.721  Millions$ 24.834  Millions
Sanofi  3.68 $ 60,063.360  Millions$ 16,339.680  Millions
Cytomx Therapeutics Inc   3.64 $ 290.435  Millions$ 79.811  Millions
Veru Inc   3.56 $ 18.820  Millions$ 5.286  Millions
Sio Gene Therapies Inc   3.46 $ 59.024  Millions$ 17.040  Millions
Travere Therapeutics Inc   3.37 $ 293.959  Millions$ 87.222  Millions
Statera Biopharma Inc fka Cytocom Inc   3.36 $ 5.592  Millions$ 1.663  Millions
Pacira Biosciences inc   3.29 $ 461.327  Millions$ 140.261  Millions
Aridis Pharmaceuticals Inc   2.93 $ 25.590  Millions$ 8.743  Millions
Ampio Pharmaceuticals inc   2.86 $ 11.825  Millions$ 4.137  Millions
Lexicon Pharmaceuticals Inc   2.80 $ 279.876  Millions$ 100.012  Millions
Esperion Therapeutics inc   2.73 $ 186.758  Millions$ 68.456  Millions
Biohaven Ltd   2.69 $ 320.111  Millions$ 118.976  Millions
Akebia Therapeutics Inc   2.63 $ 295.516  Millions$ 112.197  Millions
Cumberland Pharmaceuticals Inc  2.63 $ 52.033  Millions$ 19.785  Millions
Fortress Biotech Inc   2.55 $ 171.625  Millions$ 67.269  Millions
Zosano Pharma Corporation  2.53 $ 26.289  Millions$ 10.379  Millions
Urovant Sciences Ltd   2.44 $ 58.007  Millions$ 23.756  Millions
Chemocentryx Inc.  2.43 $ 150.459  Millions$ 61.862  Millions
Aptevo Therapeutics Inc   2.41 $ 36.396  Millions$ 15.117  Millions
Progenics Pharmaceuticals Inc  2.37 $ 73.543  Millions$ 30.991  Millions
Optinose Inc   2.36 $ 104.859  Millions$ 44.518  Millions
Apellis Pharmaceuticals Inc   2.33 $ 324.491  Millions$ 139.562  Millions
Alexion Pharmaceuticals Inc   2.23 $ 4,281.000  Millions$ 1,919.700  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com